Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
应用场景：
创建时间：
2022-05-15
相关数据集
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors
The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: 1. what is the max
NIAID Data Ecosystem60
Feasibility study of a short Bevacizumab infusion in patients.
Interventions: Bevacizumab is administered in 0.5mg/kg/min. Primary outcome(s): Having onset of hypersensitivity reaction or not Study Design: Single arm Non-randomized
NIAID Data Ecosystem20
Dataset from Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients
The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractor
NIAID Data Ecosystem10
Table_5_Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis.docx
Background: Head-to-head evidence is lacking in comparative risks of high-grade adverse events (AEs) among different systemic treatment options for advanced melanoma. Methods: An up-to-date systematic
NIAID Data Ecosystem50
Table1_Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.docx
Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syn
NIAID Data Ecosystem20
